The aim of our study was to investigate the application of contrast-enhanced ultrasound (CEUS) and its quantification analysis for the prediction of early treatment response of @entity2857 on @entity95 VX2 @entity96 model. @entity95 were implanted VX2 @entity5 mass to establish a @entity96 model. Fourteen days after @entity5 implantation, @entity95 presented with single @entity96 were randomly divided into two groups. @entity95 in treatment group were given by gavage once a day for 14  days with @entity2857 suspension at a dose of 30  mg/kg, whereas @entity95 in control group were given saline by gavage of the same volume. CEUS was performed before treatment and 3, 7, 14  days after treatment for the analysis of @entity5 size, enhancement pattern, and @entity39 range. The time intensity curve (TIC) was used to obtain quantitative parameters of enhancement patterns. Before @entity2857 administration, @entity5 volumes ranged from 0.24 to 0.75  cm(3) (mean 0.49        0.18  cm(3)) in treatment group and 0.24 to 0.44  cm(3) (mean 0.30        0.12  cm(3)) in control group. The dynamic enhancement patterns of @entity5 were homogeneous @entity14782 (n   =   8), @entity14782 (n   =   4), and peripheral rim-like enhancement (n   =   2). All @entity5 of the treatment group presented with peripheral rim-like enhancement with large @entity39 area after @entity2857 administration, whereas @entity5 of the control group showed @entity14782 (n   =   5) and peripheral rim-like enhancement (n   =   2). There was a significant difference in area under the curve (AUC) before and after @entity2857 treatment (P   =   0.045). CEUS may be of value in the evaluation of early therapeutic response after @entity2857 administration.

Early treatment response to @entity2857 for @entity95 VX2 orthotic XXXX : evaluation by quantitative contrast-enhanced ultrasound.

@entity39 :: ('MESH:D009336', 'Disease') :: ['necrotic', 'necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity96 :: ('MESH:D008113', 'Disease') :: ['liver tumor'] @entity14782 :: ('MESH:C564835', 'Disease') :: ['hyper-enhancement', 'heterogeneous hyper-enhancement'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib'] @entity95 :: ('9986', 'Species') :: ['Rabbits', 'rabbits', 'rabbit']
@entity96 :: (MESH:D008113,Disease) :: ['liver tumors']
